Posted by Michael Wonder on 30 May 2018
TrioxBio announces fast track designation granted by U.S. FDA to Raviten for the treatment of intradialytic hypotension
29 May 2018 - Phase II clinical trials in patients undergoing hemodialysis to be initiated in Q4, 2018.
TrioxBio today announced that the U.S. FDA has granted fast track designation for Raviten (MTR-107) for the reduction in hospitalisations or death in patients with end-stage renal disease undergoing haemodialysis and predisposed to developing intradialytic hypotension.
The Company plans to initiate Phase II clinical trials for Raviten in the United States later this year.
